Publication:
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Simple item page
dc.contributor.authorFernandez Rivera, Constantino
dc.contributor.authorCalvo Rodríguez, María
dc.contributor.authorPoveda, José Luís
dc.contributor.authorPascual, Julio
dc.contributor.authorCrespo, Marta
dc.contributor.authorGomez, Gonzalo
dc.contributor.authorCabello Pelegrin, Sheila
dc.contributor.authorPaul, Javier
dc.contributor.authorLauzurica, Ricardo
dc.contributor.authorPerez Mir, Mònica
dc.contributor.authorMoreso, Francesc
dc.contributor.authorPerelló, Manel
dc.contributor.authorAndres, Amado
dc.contributor.authorGonzález, Esther
dc.contributor.authorFernandez, Ana
dc.contributor.authorMendiluce, Alicia
dc.contributor.authorFernández Carbajo, Beatriz
dc.contributor.authorSanchez Fructuoso, Ana
dc.contributor.authorCalvo, Natividad
dc.contributor.authorSuarez, Alejandro
dc.contributor.authorBernal Blanco, Gabriel
dc.contributor.authorOsuna, Antonio
dc.contributor.authorRuiz-Fuentes, M Carmen
dc.contributor.authorMelilli, Edoardo
dc.contributor.authorMontero Perez, Nuria
dc.contributor.authorRamos, Ana
dc.contributor.authorFernández, Beatriz
dc.contributor.authorLópez, Verónica
dc.contributor.authorHernandez, Domingo
dc.contributor.authorBetter study
dc.date.accessioned2024-02-19T15:32:25Z
dc.date.available2024-02-19T15:32:25Z
dc.date.issued2021-12-17
dc.description.abstractMulticenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P 
dc.format.number3es_ES
dc.format.pagee14550es_ES
dc.format.volume36es_ES
dc.identifier.doi10.1111/ctr.14550
dc.identifier.e-issn1399-0012es_ES
dc.identifier.journalClinical transplantationes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/19932
dc.identifier.pubmedID34851532es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18521
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectbioavailability
dc.subjectclinical practice
dc.subjectpharmacokinetics
dc.subjectrenal transplantation
dc.subjecttacrolimus
dc.subjecttreatment failure
dc.subject.meshBiological Availability
dc.subject.meshDrug Administration Schedule
dc.subject.meshGraft Rejection
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents
dc.subject.meshKidney Transplantation
dc.subject.meshProspective Studies
dc.subject.meshTacrolimus
dc.subject.meshTransplant Recipients
dc.titleBioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)